Asthma is a global epidemic that affects over 25 million Americans and more than 350 million people worldwide. Approximately 5%-10% of severe asthmatics do not respond to conventional therapy. For these patients their condition is life-threatening.
PulmoGeniX is focused initially on delivering a cost-effective, device-based treatment that combines physiologic metrics and real-time biofeedback with therapeutic intervention to diagnose and treat bronchial smooth muscle within one procedural visit to dramatically decrease asthma attacks in severe asthma patients.
The PulmoGenix business strategy is to promote a cost-effective, single-use, disposable, therapeutic intervention that evolves the current paradigm of asthma treatment in order to swiftly gain market share in the existing markets and to drive new sector growth in both the developed and the emerging global markets.
Significant Unmet Clinical Need:
The unmet clinical need to treat severe asthmatics is immense. The acute, chronic asthma patient population is represented by more than 2 million severe asthma patients in the U.S. and 8 million worldwide. In addition, a 25% overall increase in patient population is projected by 2025.
Asthma is an inflammatory disorder of the airways, which causes attacks of wheezing, shortness of breath, chest tightness, and coughing. During an asthma attack, the muscles surrounding the airways become tight, and the lining of the air passages swells. Asthma symptoms can be triggered by breathing in allergy-causing substances, such as pollen and dust.
Significant Competitive Advantages:
The first and only non-drug therapy for asthma is a novel procedure, known as Bronchial Thermoplasty, that delivers thermal energy to the airways to reduce excess airway smooth muscle that is associated with airway constriction in patients with asthma. By decreasing the ability of the airways to constrict, this new treatment has been shown to help patients with severe asthma gain substantially better control over their disease.
The drawbacks of Bronchial Thermoplasty are that it requires at least three operative procedures over 3 months. In addition to being a belabored, time-consuming therapy, the procedure is expensive, technically challenging for physicians, and burdensome to the patient.
PulmoGeniX's collaboration with Mayo Clinic in both the inception of certain aspects of the technology and their ongoing participation in the development, clinical investigation and study of the technology is significant to improving Patient care.
PulmoGeniX™, in coordination with Mayo Clinic, is developing a comprehensive device based treatment intended to diagnose and treat asthma. The technology was invented to reduce bronchial smooth muscle to eliminate its ability to constrict and, thus, dramatically decrease asthma attacks. It is designed to treat a greater number of airways simultaneously, to be less technically challenging for the physician, to be performed within one procedural visit and to be less expensive for the patient.